Shire Withdraws Replagal BLA Rather Than Conduct Lengthy Trials – Updated
This article was originally published in The Pink Sheet Daily
Executive Summary
Distributed free of charge to U.S. patients with Genzyme’s Fabrazyme in short supply, Replagal seemed destined for quick approval, but FDA has signalled otherwise.